Atezolizumab/hyaluronidase
Combination medication
- 1 min read
- 2 chapters
Explore on Lably
ToursExplore Lably’s 3D toursThe most common adverse reactions include fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.
Atezolizumab/hyaluronidase was approved for medical use in the United States in September 2024.
Medical uses
Atezolizumab/hyaluronidase is a subcutaneous injection version of atezolizumab for all the adult indications as the intravenous formulation of atezolizumab including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.
Sign in to keep reading
One more chapter is free with a Lably account.
History
The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. A total of 371 participants were randomized (2:1) to receive subcutaneous atezolizumab and hyaluronidase or intravenous atezolizumab until disease progression or unacceptable toxicity.